

DOUGLAS TSAO JOINS H.C. WAINWRIGHT AS SENIOR BIOPHARMA ANALYST

NEW YORK, November 6, 2018 - H.C. Wainwright & Co., LLC ("HCW"), a leading investment bank focused on capital markets and equity research in the Life Sciences sector, is pleased to announce that Douglas D. Tsao has joined the firm as a Managing Director, Equity Research.

Prior to joining HCW, Mr. Tsao was a senior equity research analyst at Barclays covering U.S. Specialty Pharmaceutical companies. Mr. Tsao is recognized for his expertise in biosimilars and is a frequent speaker on this topic at industry conferences. Previously, he covered small and midcap medical device companies at Barclays and began his career in equity research at Lehman Brothers, where he covered healthcare distribution and technology companies. He served as a Special Assistant to U.S. EPA Administrator Carol Browner from 1997-1999, received an MBA/MPH from U.C. Berkeley and graduated cum laude from Middlebury College with High Honors.

"We are excited that Doug has chosen to become a member of the research team at HCW," commented Mark Viklund, HCW's Chief Executive Officer. "He will be a valued addition to our franchise of 11 senior analysts covering the Life Sciences sector as we continue to expand our breadth of coverage across the market capitalization spectrum."

About H.C. Wainwright & Co., LLC

H.C. Wainwright & Co., LLC is an investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private growth companies across multiple sectors and regions. The H.C. Wainwright team has been the leader in the CMPO (Confidentially Marketed Public Offering), PIPE (private investment in public equity) and RD (registered direct offering) transaction markets. H.C. Wainwright was established in 1868 and is headquartered in New York City.